SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ocular Therapeutix, Inc. -- OCUL

NEW YORK, July 7, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ocular Therapeutix, Inc. ("Ocular" or the "Company") (NASDAQ: OCUL).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Ocular and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action]

On July 6, 2017, shortly before the end of the trading day, the website Seeking Alpha published an article entitled "Ocular: A Poke In The Eye", reporting, in part, that the Company's management had misled Ocular investors regarding ongoing manufacturing issues and downplayed the significance of U.S. Food and Drug Administration communications regarding these issues. 

On this news, Ocular's share price fell $0.68, or 6.68%, to close at $9.50 on July 6, 2017, and has fallen an additional $1.20, or 12.6%, during intraday trading on July 7, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ocular-therapeutix-inc----ocul-300484736.html

SOURCE Pomerantz LLP